PMID- 25473263
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20141204
LR  - 20200930
IS  - 1177-5467 (Print)
IS  - 1177-5483 (Electronic)
IS  - 1177-5467 (Linking)
VI  - 8
DP  - 2014
TI  - Effects of Systane((R)) Balance on noninvasive tear film break-up time in patients 
      with lipid-deficient dry eye.
PG  - 2365-72
LID - 10.2147/OPTH.S70623 [doi]
AB  - PURPOSE: To evaluate the ability of Systane((R)) Balance (SYSB) administered four 
      times per day for 4 weeks to increase noninvasive tear film break-up time 
      (NITFBUT) over baseline compared with a saline (SAL) control in patients with 
      lipid-deficient dry eye (DE). PATIENTS AND METHODS: Patients aged >/=18 years with 
      DE and evidence of meibomian gland dysfunction (ie, abnormal gland expression and 
      missing meibomian glands) were included in this randomized, parallel-group, 
      controlled, investigator-masked comparison study. Patients were randomized to 
      SYSB or SAL four times daily for 4 weeks. The primary efficacy variable was mean 
      change in NITFBUT from baseline at week 4. Ocular surface staining, goblet cell 
      density, and meibomian gland expression were also assessed. Safety assessments 
      included adverse events (AEs), best-corrected visual acuity, and ocular signs. 
      RESULTS: A total of 49 patients received study treatments (SYSB, n=25; SAL, 
      n=24). Most patients were women (67.4%) and Caucasian (63.3%); mean +/- standard 
      deviation (SD) age was 44+/-19 years. DE characteristics at baseline were similar 
      between groups. After 4 weeks of treatment, the mean +/- SD NITFBUT increase from 
      baseline was significantly greater with SYSB (2.83+/-0.74 seconds) compared with 
      SAL (0.66+/-0.55 seconds; P<0.001, t-test). Improvements in conjunctival and 
      corneal staining, percentage of patients with increased goblet cell density, and 
      meibomian gland expression were also observed with 4 weeks of SYSB over SAL. No 
      AEs were reported for either treatment group; best-corrected visual acuity and 
      ocular signs remained stable or improved compared with baseline. CONCLUSION: SYSB 
      restored tear film stability, improved ocular surface healing, and improved 
      meibomian gland functionality after 4 weeks of use in patients with 
      lipid-deficient DE. No AEs were reported with either SYSB or SAL.
FAU - Aguilar, Alejandro J
AU  - Aguilar AJ
AD  - Universidad de Buenos Aires, Buenos Aires, Argentina.
FAU - Marquez, Maria I
AU  - Marquez MI
AD  - Universidad de Buenos Aires, Buenos Aires, Argentina.
FAU - Albera, Paula A
AU  - Albera PA
AD  - Universidad de Buenos Aires, Buenos Aires, Argentina.
FAU - Tredicce, Jorge L
AU  - Tredicce JL
AD  - Universidad de Buenos Aires, Buenos Aires, Argentina.
FAU - Berra, Alejandro
AU  - Berra A
AD  - Universidad de Buenos Aires, Buenos Aires, Argentina.
LA  - eng
PT  - Journal Article
DEP - 20141125
PL  - New Zealand
TA  - Clin Ophthalmol
JT  - Clinical ophthalmology (Auckland, N.Z.)
JID - 101321512
PMC - PMC4251748
OTO - NOTNLM
OT  - artificial tears
OT  - conjunctival staining
OT  - corneal staining
OT  - goblet cells
EDAT- 2014/12/05 06:00
MHDA- 2014/12/05 06:01
PMCR- 2014/11/25
CRDT- 2014/12/05 06:00
PHST- 2014/12/05 06:00 [entrez]
PHST- 2014/12/05 06:00 [pubmed]
PHST- 2014/12/05 06:01 [medline]
PHST- 2014/11/25 00:00 [pmc-release]
AID - opth-8-2365 [pii]
AID - 10.2147/OPTH.S70623 [doi]
PST - epublish
SO  - Clin Ophthalmol. 2014 Nov 25;8:2365-72. doi: 10.2147/OPTH.S70623. eCollection 
      2014.